Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir implant in low-risk HIV-negative participants
NCT05115838Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with >=1 adverse events at 60 weeks and Percentage of participants withdrawing from study treatment due to adverse event at 52 weeks. Planned start Jan 2024; status: withdrawn.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05115838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115838.